S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:NCNA

NuCana Stock Forecast, Price & News

$5.29
-0.06 (-1.12 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.17
Now: $5.29
$5.41
50-Day Range
$4.57
MA: $5.21
$5.69
52-Week Range
$3.81
Now: $5.29
$10.59
Volume92,793 shs
Average Volume151,174 shs
Market Capitalization$171.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More
NuCana logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NCNA
CUSIPN/A
Phone44-0-13-1357-1111
Employees29

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Market Cap$171.81 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$5.29
-0.06 (-1.12 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NuCana (NASDAQ:NCNA) Frequently Asked Questions

How has NuCana's stock been impacted by COVID-19?

NuCana's stock was trading at $6.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NCNA stock has decreased by 16.6% and is now trading at $5.29.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NuCana?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for NuCana
.

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for NuCana
.

How were NuCana's earnings last quarter?

NuCana PLC (NASDAQ:NCNA) announced its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03.
View NuCana's earnings history
.

What price target have analysts set for NCNA?

5 equities research analysts have issued twelve-month target prices for NuCana's shares. Their forecasts range from $15.00 to $21.00. On average, they expect NuCana's share price to reach $17.50 in the next year. This suggests a possible upside of 230.8% from the stock's current price.
View analysts' price targets for NuCana
.

Are investors shorting NuCana?

NuCana saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 1,240,000 shares, a decrease of 57.1% from the September 15th total of 2,890,000 shares. Based on an average daily volume of 230,800 shares, the short-interest ratio is presently 5.4 days. Approximately 4.3% of the shares of the company are sold short.
View NuCana's Short Interest
.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 74)
  • Mr. Hugh S. Griffith, Founder, CEO & Director (Age 52)
  • Mr. Donald Munoz, Chief Financial Officer (Age 51)

When did NuCana IPO?

(NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $5.29.

How big of a company is NuCana?

NuCana has a market capitalization of $171.81 million. The company earns $-27,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. NuCana employs 29 workers across the globe.

What is NuCana's official website?

The official website for NuCana is www.nucana.com.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.